Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Enrolling By Invitation
18-99 years
All
Phase 1
7 participants needed
1 Location

Brief description of study

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: solid tumors
  • Age: Between 18 Years - 99 Years
  • Gender: All

Male or female age 18 or older Measurable tumor

Updated on 01 Aug 2024. Study ID: 849870
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research